Ed Schoonveld

For drugs already on the market, there may be little companies can do to limit business impact; however, for new development drugs, there are some critical considerations.

CMS’s Globe and Guard models extend MFN pricing into Medicare Part B and Part D, signaling a sweeping shift in US drug pricing policy.

Various agreements with the Trump administration could have long-term ramifications for Medicaid access and global pricing strategy.

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, exploring US price-referencing guidance, its impact on innovation, and whether this marks the beginning of broader pricing controls.

In the second part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, notes that while non-transferability could hinder smaller biotechs partnering late with pharma, most alliances are already in place before vouchers become relevant.

In the first part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, explains that affordability is only one pathway to securing a voucher—and reducing list prices isn’t the only way to demonstrate value.

Amid pressures on pharma to match the lowest international prices, experts warn of “policy laundering” and discriminatory impact.

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.

A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.

How practical is this form of pricing in the pharma setting?

Respective industry and government agendas could significantly reshape the US prescription drug market.

Finding the optimal balance in pharmacy benefit manager reform.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

As the dust settles on the first round of Medicare negotiations, not everything is what it seems.

Balancing innovation focus with optimized decision-making.

The impact of income-based price controls in healthcare.

Fighting for patient affordability doesn’t necessarily require a scapegoat.

The debate continues as to how government payers should weigh covering healthcare needs versus other budget items.

A dive into the issue of evidence gaps, plus the case for a chief access officer.

The latest on its implementation—and the implications for biopharma.

How various factors are affecting the amount of funds allocated to healthcare.